# Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

> **NCT02909452** · PHASE1 · COMPLETED · sponsor: **Syndax Pharmaceuticals** · enrollment: 30 (actual)

## Conditions studied

- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms by Histologic Type
- Bronchial Neoplasms
- Lung Neoplasms
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Lung Diseases
- Breast Diseases
- Renal Neoplasm
- Solid Tumors

## Interventions

- **DRUG:** Entinostat
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02909452
- **Lead sponsor:** Syndax Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-20
- **Primary completion:** 2019-07-17
- **Final completion:** 2021-02-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02909452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02909452, "Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02909452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*